Deep Brain Stimulation in the Treatment of Obsessive-compulsive Disorder: Current Perspectives
Overview
Affiliations
Deep brain stimulation (DBS) is a neuro-psychosurgical technique widely accepted in movement disorders, such as Parkinson's disease. Since 1999, DBS has been explored for severe, chronic and treatment-refractory psychiatric diseases. Our review focuses on DBS in obsessive-compulsive disorder (OCD), considered as a last treatment resort by most of learned societies in psychiatry. Two main stimulation areas have been studied: the striatal region and the subthalamic nucleus. But, most of the trials are open-labeled, and the rare controlled ones have failed to highlight the most efficient target. The recent perspectives are otherwise encouraging. Indeed, clinicians are currently considering other promising targets. A case series of 2 patients reported a decrease in OCD symptoms after DBS in the medial forebrain bundle and an open-label study is exploring bilateral habenula stimulation. New response criteria are also investigating such as quality of life, or subjective and lived-experience. Moreover, first papers about cost-effectiveness which is an important criterion in decision making, have been published. The effectiveness of tractography-assisted DBS or micro-assisted DBS is studying with the aim to improve targeting precision. In addition, a trial involving rechargeable pacemakers is undergoing because this mechanism could be efficient and have a positive impact on cost-effectiveness. A recent trial has discussed the possibility of using combined cognitive behavioral therapy (CBT) and DBS as an augmentation strategy. Finally, based on RDoc Research, the latest hypotheses about the understanding of cortico-striato-thalamo-cortical circuits could offer new directions including clinical predictors and biomarkers to perform adaptive closed-loop systems in the next future.
Knebel J, McClure R, Kennedy M J Clin Med. 2024; 13(21).
PMID: 39518688 PMC: 11546672. DOI: 10.3390/jcm13216549.
Behavioral disorders in Parkinson disease: current view.
Jellinger K J Neural Transm (Vienna). 2024; 132(2):169-201.
PMID: 39453553 DOI: 10.1007/s00702-024-02846-3.
Bernardi D, Shannahoff-Khalsa D, Sale J, Wright J, Fadiga L, Papo D Front Psychiatry. 2023; 14:1158404.
PMID: 37234212 PMC: 10208430. DOI: 10.3389/fpsyt.2023.1158404.
Landscape and future directions of machine learning applications in closed-loop brain stimulation.
Chandrabhatla A, Pomeraniec I, Horgan T, Wat E, Ksendzovsky A NPJ Digit Med. 2023; 6(1):79.
PMID: 37106034 PMC: 10140375. DOI: 10.1038/s41746-023-00779-x.
Non-Pharmacological Therapeutic Options for the Treatment of Alzheimer's Disease.
Huynh Q, Elangovan S, Holsinger R Int J Mol Sci. 2022; 23(19).
PMID: 36232336 PMC: 9570337. DOI: 10.3390/ijms231911037.